Michael Bryer-Ash, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1649205899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 28.6% of the total. Reporting peaked in 2019 at $1,935 and has fallen 90.3% since, to $187 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.
Across 85 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$688
- Boehringer Ingelheim$333
- Mannkind Corporation$185
- AbbVie$153
- Lilly USA, LLC$151
- Dexcom, Inc.$146
- plus $748 from 14 others
Across 1 payment — averaging $480.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$481
What the payments were for
- Food & beverage$2,404100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $688 |
| Boehringer Ingelheim | 13 | $333 |
| Mannkind Corporation | 9 | $185 |
| AbbVie(2 entities) | 7 | $153 |
| Lilly USA, LLC | 8 | $151 |
| Dexcom, Inc. | 2 | $146 |
| Amgen | 3 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Insulet Corporation | 5 | $109 |
| Abbott | 5 | $93 |
| AstraZeneca | 5 | $74 |
| Shire North American Group Inc | 3 | $50 |
| Medtronic | 2 | $38 |
| Johnson & Johnson | 3 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$139
- INVOKANA$123
- Tresiba$120
- JARDIANCE$113
- AFREZZA$107
How this compares
$2,404 in reported general payments places this provider in the 45th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 679 | $638,028 |
| JardianceEmpagliflozin | 445 | $263,131 |
| TrulicityDulaglutide | 135 | $131,265 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 44 | $59,600 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $13,242 |
| Novolog FlexpenInsulin Aspart | 77 | $12,522 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 145 | $10,441 |
| Atorvastatin Calcium | 302 | $5,697 |
| AlogliptinAlogliptin Benzoate | 23 | $4,459 |
| Insulin Glargine-Yfgn | 31 | $3,603 |
| SynthroidLevothyroxine Sodium | 204 | $3,588 |
| Ezetimibe | 169 | $2,114 |
| Amlodipine Besylate | 147 | $1,889 |
| Fenofibrate | 175 | $1,818 |
| Pioglitazone Hcl | 324 | $1,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $688 | $638,028679 claims |
| Boehringer IngelheimJardiance | $333 | $263,131445 claims |
| Lilly USA, LLCTrulicity | $151 | $131,265135 claims |
| AbbVieSynthroid | $153 | $3,588204 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.